P1, N=10, Recruiting, University of Texas Southwestern Medical Center | Not yet recruiting --> Recruiting

In preclinical models, pharmacological agents including montelukast, zileuton, and FLAP antagonists suppress tumor growth, and restore apoptotic signaling; current clinical evidence remains largely observational and pharmacoepidemiologic. Targeting this pathway represents a promising avenue in oncology, with potential to enhance precision medicine through biomarker-guided patient stratification. Further clinical validation is warranted to translate these findings into therapeutic benefit.

Moreover, the CK aqueous extract decreased MDA ( ) and increased T-AOC, GSH-Px, and SOD in sheep liver ( ) and decreased TNF- , IL-2, and IL-6 ( ) and increased IL-10, IgM, and IgG in the thymus and spleen ( ). These results suggest that the addition of CK aqueous extract can promote sheep growth and improve oxidative stress, inflammation, and immune response to chronic cold stimulation in sheep.

Similarly, SA-treated rats exhibited attenuation of hepatorenal inflammation via diminished TNF-α and IL-6 levels. SA exerted a hepatorenal protective effect in rats by exhibiting antioxidant and anti-inflammatory activities.

P2, N=95, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027

This case highlights the complexity of diagnosing SS, given its subtle clinical findings, slow growth, and atypical presentation. Multidisciplinary care is essential for optimizing diagnosis and treatment outcomes. Prompt recognition and comprehensive care can improve patients' prognosis.

In addition, BLPs-SeNPs showed stronger inhibitory and pro-apoptotic effects on tumor cells than BLPs alone. Overall, these results indicate that BLPs can serve as effective natural stabilizers for selenium nanoparticles and that the resulting BLPs-SeNPs possess promising in vitro bioactivities.

The present study investigates the anticancer therapeutic potential of two MTAs, MitoQ, and Mito-TEMPO, in rodent N-nitrosodiethylamine-induced hepatic cancer...The combination treatment of these two MTAs also exhibited additive anticancer therapeutic potential on tumor profile. Therefore, MTA-based anticancer therapy approach holds a promising future.

Immunofluorescence further revealed that PASN rescued the expression of brain-derived neurotrophic factor (BDNF) (hACs: 35.23%, PC12: 12.50%) and glutamate decarboxylase (GAD1/2) (hACs: 102.66%, PC12: 31.31%), key markers associated with synaptic plasticity and GABAergic sleep regulation. Collectively, PASN is a thermally stable squid-derived peptide fraction that exerts antioxidant and cytoprotective effects in neural cell models in vitro and represents a promising sustainable candidate for nutraceutical development.

Critically, while zileuton remains the sole clinically approved lipoxygenase-targeting drug, it is clinically used as a 5-LOX inhibitor for asthma and is not an h15-LOX-2-targeted therapy...Outstanding challenges including the scarcity of ex vivo validated compounds, species-specific translational barriers arising from divergent murine ortholog function, and the absence of wild-type inhibitor co-crystal structures are critically evaluated. Future directions encompassing covalent inhibitor strategies, PROTAC-based targeted degradation, and selective modulation of the pro-ferroptotic h15-LOX-2/PEBP1 complex are discussed as promising avenues to fully realize the therapeutic potential of this target.

Here, we found that two antioxidants, glutathione (GSH) and N-acetylcysteine (NAC), stabilized BACH1 (i.e., BTB and CNC homology 1) by decreasing ROS levels, thus facilitated BACH1-dependent migration of HCC cells in vitro and their metastasis in vivo...The BACH1-regulated metabolic reprogramming was further unraveled by non-targeted metabolomics. Collectively, these demonstrate that the redox-sensitive transcription factor BACH1 functions as a crucial metastasis-promoter of HCC, and thus antioxidants stimulate BACH1-dependent HCC metastasis.

These observations imply an increased solubilization and elastovesicular behaviour of spanlastic nanoparticles with enhanced bioactivity of rutin. In conclusion, rutin spanlastic nanoparticles are an efficient delivery vehicle compared to rutin nanocrystals or free rutin in amplifying both antioxidant and anticancer activity, hence warranting further in vivo experiments to treat breast carcinoma.